Dr. Ajit Shetty
Dr. Shetty has extensive pharmaceutical experience leading commercial and supply chain operations and a significant educational background, including a Ph.D. in Metallurgy from Trinity College at Cambridge University. Dr. Shetty spent 36 years at Johnson & Johnson (“J&J”) in a wide range of global roles. From 2007 to 2012, he served as Corporate Vice President, Enterprise Supply Chain, reporting to the CEO and was responsible for the transformation and optimization of J&J’s supply chain. In addition, from 2004 to 2012, he served as chairman of Janssen Pharmaceutical.
In recognition of his unique services as a business leader, Dr. Shetty was awarded the Right Honourable Sir and Title of Baron by King Albert II of Belgium in 2008 and the Life-Time Achievement Award by India in 2010.
Aditya Bahl
Mr. Bahl brings over 20 years of experience in pharmaceutical marketing and clinical development. He is the CEO and founder of RAS LSS, a boutique healthcare consulting group based in Germany providing strategic guidance to biotechnology and pharmaceutical companies on franchise and product strategy, clinical development and commercialization.
Mr. Bahl, who worked as Director of Competitive Intelligence at Novartis Pharma AG and as Senior Consultant for Janssen Research and Development, is known for his entrepreneurship, creativity and is a passionate speaker for innovations in healthcare. He has significant leadership experience across several therapeutic areas, including oncology and biosimilars.
Bryan Jones
Bryan Jones, PhD., has more than 30 years of experience with Biotech and Specialty Pharmaceutical companies with roles in product and business development. Currently, he is the COO of Aardvark Therapeutics. Previously, he was COO and Co-Founder of Sollis Therapeutics, where he led the technology transfer from Medtronic, the manufacturing of a drug/device combination and the execution of the Phase 3 Sciatica program. Prior to that, as the Vice President of Operations at Sorrento Therapeutics, he led the Resiniferatoxin program, including manufacturing, toxicology and clinical planning, as well as being involved in both monoclonal antibody production, ADC research and cell therapy development.
He has held increasing responsibilities, including Chief Operating Officer of two startup companies: Sherrington and Mt. Cook. He has worked in Business Development at Amylin, and Kemia. Earlier in his career, he worked in research at Bristol-Myers Squibb and on products such as Cialis® with ICOS. Dr. Jones received his PhD. in Genetics from the University of Washington and a Bachelor’s degree in Biology and Biochemistry from Iowa State University.